Ipilimumab plus nivolumab ‘considered a cure’ long term for melanoma brain metastasis
Source: Healio, April 2025
Key takeaways:
- The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.
- Similarly, 48% of those patients achieved a 7-year overall survival.
Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option.
First published in 2018, results from the Anti-PD-1 Brain Collaboration (ABC) trial showed that intracranial ipilimumab plus nivolumab treatment could slow the progression of melanoma brain metastases — a finding that “changed practice overnight” according to Georgina V. Long, PhD, MBBS, FRACP, AAHMS, professor at the University of Sydney, comedical director of Melanoma Institute Australia and chair of melanoma medical oncology and translational research at Melanoma Institute Australia and Royal North Shore Hospital.